July 30 - 13:07
Biofourmis' heart failure digital therapy receives FDA breakthrough device designation
Digital therapeutics company Biofourmis's BiovitalsHF, a platform designed for heart failure medication monitoring, received an FDA breakthrough device designation. BiovitalsHF helps patients adjust the dosage of their medications accurately using a wearble device. Currently, less than 1% of heart failure patients receive the optimal dose of their medication on a regular basis.
> Tweets